Jonathan B. Zung - May 21, 2024 Form 4 Insider Report for CURIS INC (CRIS)

Role
CDO
Signature
/s/ Diantha Duvall, Attorney-in-fact
Stock symbol
CRIS
Transactions as of
May 21, 2024
Transactions value $
$472,934
Form type
4
Date filed
5/23/2024, 04:10 PM
Previous filing
May 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRIS Employee stock option (right to buy) Award $473K +40.7K $11.62 40.7K May 21, 2024 Common Stock 40.7K $11.62 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 19, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to, among other things, increase the number of shares authorized for issuance thereunder and increase the per participant limit on the number of shares subject to awards that can be granted annually to participants in the plan; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan.
F2 The option grant described in this Form 4 filing vests as to 25% of the original shares on January 19, 2025 and as to an additional 6.25% of the original shares each successive quarter and until January 19, 2028.